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Strengths and limitations of this study
 ► A comprehensive review of the utility of Ki-67 as 
a prognostic marker in pulmonary neuroendocrine 
tumours will be performed following the key meth-
odological steps of Preferred Reporting Items for 
Systematic Review and Meta-Analysis Protocols 
guidelines.
 ► A meticulous search will be carried out for the rel-
evant studies from several databases endeavouring 
to capture all the relevant published literature.
 ► Papers not published in English will be excluded and 
therefore, significant outcomes could be overlooked.
 ► It is anticipated that there may be significant inter-
study heterogeneity in how results will be reported, 
the cut-off points for Ki-67 percentage or other is-
sues. Accordingly, it may not be possible to conduct 
a meta-analysis, particularly if only a limited number 
of articles are identified with sufficient information.
AbStrACt
Introduction The omission of the immunohistochemical 
proliferation marker Ki-67 labelling index (henceforth, 
simply Ki-67) from the 2015 WHO classification system 
of pulmonary neuroendocrine tumours (Lung-NETs) as a 
prognostic and grading criterion remains controversial. 
This systematic review along with meta-analysis will be 
conducted to assess the prognostic/grading utility of Ki-67 
in Lung-NETs.
Methods This systematic review will be conducted 
in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis guidelines. A 
systematic search of MEDLINE Ovid, Embase, Scopus and 
the Cochrane Library will be performed from the inception 
of each database to 28 February 2019 for studies 
investigating any role of Ki-67 in Lung-NETs. Only full 
papers published in English detailing survival outcomes 
and HRs according to Ki-67 will be included. The primary 
endpoint will be establishing whether Ki-67 is a reliable 
marker in determining prognosis and thus assessing grade 
of Lung-NETs patients.
Ethics and dissemination Ethical approval will not 
be required as this is an academic review of published 
literature. Findings will be disseminated through the 
preparation of a manuscript for publication in a peer-
reviewed journal as well as presentation at national and 
international conferences.
PrOSPErO registration number CRD42018093389
IntrOduCtIOn
Neuroendocrine tumours (NETs) represent 
an extremely heterogenous group of tumours. 
Almost any anatomical site can be affected and 
the clinical behaviour of these tumours also 
varies considerably. Approximately 27% of all 
NETs arise within the lungs and the incidence 
of pulmonary neuroendocrine tumours (Lung-
NETs) is increasing for reasons which are still 
unclear.1–3 One factor is likely to be an increase 
in incidental diagnoses as a result of advances 
in diagnostic imaging performed for unrelated 
reasons.
Ki-67 is a DNA-binding nuclear protein 
which was discovered by Gerdes et al in 1983.4 
It is expressed throughout all phases of the 
cell cycle, besides the quiescent G0 phase. 
As a result, its main clinical utility is in distin-
guishing between proliferating and non-pro-
liferating cells. Ki-67 is a robust biomarker of 
proliferation in malignancy given its qualities 
of tight cell cycle regulation and rapid degrada-
tion after the completion of mitosis (Ki-67 has 
a short half-life of 1–1.5 hours), where it acts 
as a biological surfactant to disperse mitotic 
chromosomes.5 The gene encoding the Ki-67 
protein has been termed MKI67 and is located 
on chromosome 10q26.6
Most frequently, Ki-67 is quantified by immu-
nohistochemistry as a score or labelling index 
(LI) based on the percentage of tumour cells 
which stain positively (usually a minimum of 
500 cells, with best practice being to count 2000 
cells or 2 mm2) usually in areas of most dense 
staining.7 8 Ki-67 is regarded as a more accurate 
measure of cell proliferation in comparison to 
mitotic figure counting. Immunohistochem-
ical evaluation, however, is not without its 
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Table 1 Modified from WHO diagnostic criteria for pulmonary NETs 2015
TC AC LCNEC SCLC
Mitoses <2 2–10 >10 >10
Necrosis Absent If present, usually focal or 
punctate
Extensive Extensive
Morphology Organoid Organoid Organoid Small cell
Differentiation grade Low Intermediate High High
AC, atypical carcinoid; LCNEC, large cell neuroendocrine carcinoma; NETs, neuroendocrine tumours; SCLC, small cell lung carcinoma; 
TC, typical carcinoid.
challenges. Manual tumour cell counting is onerous, typi-
cally taking ~40 min to complete when using slide photog-
raphy and/or other digital methods to prepare a field for 
tumour cell counting of the required number of cells. Some 
pathologists therefore use the ‘eyeball’ counting method 
which is less accurate, and varies according to pathologist’s 
experience. This subjective approach is closely related to 
the observers’ experience and thus has been criticised for its 
imprecision resulting in interobserver variability.9 Another 
proposed method to achieve uniformity and improve the 
practicality of counting (in terms of time limitations) is 
digital image analysis. However, computer-assisted methods 
are not currently in widespread use due to lack of avail-
ability and technical inaccuracy in overcounting unwanted 
cells or underestimating negative elements. Low interob-
server variation has been heralded by using camera-cap-
tured printed images, but the problem still remains in the 
choice of tumour areas subjected to counting due to the 
huge intra-tumoural heterogeneity of Ki-67, thus leading 
to significantly different scores.10 Further complexity is that 
Ki-67 may change over time either due to the natural history 
of the disease or as a result of treatment-based pressures.11
Multiple studies across a range of malignancies (eg, breast, 
prostate and NETs at several anatomical sites) have deter-
mined that there is a significant association between the 
tumour proliferation as assessed by Ki-67 LI and the patient 
survival.12–16 In breast cancer, two significant meta-analyses 
dealing with over 40 000 patients demonstrated the inde-
pendent prognostic value of Ki-67, with high Ki-67 indices 
being associated with incremental risk of relapse together 
with poorer overall survival in both node negative and node 
positive disease.12 17 Nevertheless, the debate regarding the 
intrinsic reliability issues continues among clinicians, with 
the American Society of Clinical Oncology tumour marker 
expert panel on breast cancer stating that it does not 
recommend the use of Ki-67 to assess prognosis.18 However, 
further research into the utility of Ki-67 as a prognostic 
biomarker is warranted given its advantages compared 
with newer genomic based biomarkers, including low cost, 
worldwide experience of the use of this marker by patholo-
gists, clinical relevance and reproducible results when strict 
counting guidelines are applied.19
Lung-NETs are classified by the 2015 WHO on 
morphology grounds, ranging from well-differentiated 
low-grade typical carcinoids and intermediate-grade atypical 
carcinoids to poorly differentiated high-grade large cell 
neuroendocrine carcinoma and small cell lung carcinoma 
(SCLC) with no significant differences in survival between 
them.20 Therefore, while mitotic activity and necrosis are 
key factors within this classification system, these tumours 
are not further stratified into grades (table 1). Within the 
WHO 2015 classification, the only permissible role for Ki-67 
is limited to the diagnostic separation of carcinoids from 
SCLC, mainly in the setting of biopsy or cytological samples 
with crush artefacts. This places pulmonary NETs at odds 
with gastroenteropancreatic (GEP) NETs where Ki-67 was 
proposed for the first time for predicting survival. Subse-
quently, it has been used together mitotic count for tumour 
grading with a predominant role of Ki-67 over mitoses for 
dictating ultimate clinical outcomes (table 2).21–23 As a 
result, in GEP-NETs, Ki-67 has become highly influential in 
determining management approaches. More recently, the 
updated 2017 WHO classification for pancreatic neuroen-
docrine neoplasms included a formal recognition of the 
heterogeneity of pancreatic NETs.24 The amended criteria 
now contains not only a poorly differentiated grade 3 neuro-
endocrine carcinoma group but also a distinct well-differ-
entiated grade 3 NET group. However, this distinction has 
not been extended more widely despite a recent grading 
proposal of resected Lung-NETs (assessing Ki-67, mitotic 
count and necrosis) which suggests that this would be a 
valid distinction.25
The omission of Ki-67 in the Lung-NET cohort is 
likely to be due to a perceived lack of an evidence base 
surrounding its role as an independent prognostic 
factor.8 11 Nonetheless, Ki-67 LI is often required by oncol-
ogists for therapy planning and prognostic/grading assess-
ment of these tumours.26 The aim of this systematic review 
and meta-analysis is to determine whether existing studies 
support Ki-67 as a prognostic (and by extension grading) 
biomarker in the management of pulmonary neuroendo-
crine neoplasms.
MEthOdS And AnAlySIS
In accordance with Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines, a 
prospective protocol has been produced and registered 
in the PROSPERO International Registry.27
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Table 2 WHO 2017 grading system for GEP-NETs
Grade Definition
1 Mitotic count <2/10 HPF; Ki-67 <3%
2 Mitotic count=2–20/10 HPF OR Ki-67=3%–20%
3 Mitotic count =>20/10 HPF OR Ki-67 >20%
Bold Values denotes that only one of the two criteria are needed 
for classification.
GEP, gastroenteropancreatic; NETs, neuroendocrine tumours.
Table 3 Eligibility criteria
Inclusion criteria Exclusion criteria
Any studies of Ki-67 in pulmonary neuroendocrine neoplasms 
providing prognostic information.
Non-human studies.
  Non-pulmonary neuroendocrine tumours.
  Combined histological subtypes that is, both combined 
neuroendocrine neoplasms or combined non-small cell lung 
carcinomaswith lung NETs.
  Studies not available as a full manuscript.
  Less than 20 cases.
  Studies published after 28 February 2019.
  Review papers and case reports.
  Studies not published in English.
NETs, neuroendocrine tumours.
Selection criteria
For inclusion in this review, studies (both retrospective 
and prospective) will be required to provide survival data 
for a cohort of patients with Lung-NETs. Only studies 
available in full text reporting original data in English will 
be included in the review. Key exclusion criteria include 
studies published after 28 February 2019, as well as studies 
only available in abstract form. (For full eligibility criteria, 
see table 3.)
Search strategy
To identify relevant studies, a search will be conducted 
utilising the following electronic databases: Medline 
Ovid, EMBASE, the Cochrane Library and Scopus. 
The search strategy developed in Medline Ovid uses 
a combination of Mesh subject headings and free text 
terms around the two key components of ‘Ki-67’ and 
‘neuroendocrine tumours’. An example of the full 
search strategy is available in online supplementary 
file 1. This search strategy was then modified for use 
in the other databases. Furthermore, reference lists of 
included studies and relevant reviews will be screened 
for any relevant primary studies which were not identi-
fied through the database search.
Study selection
Rayyan software will be employed to facilitate the 
initial screening process and duplicated records will 
be removed. Two independent reviewers (SN and CH) 
will screen the titles and abstracts identified through 
the different databases using the prespecified eligibility 
criteria. This will be completed in a blinded fashion. 
The primary reason for elimination will be noted for all 
exclusions. The results will be cross-referenced, prior 
to analysis. In case of disagreements, a third reviewer 
(GP) will adjudicate and then a consensus decision 
will be reached. Those studies deemed to meet the 
initial screening will then undergo a further full text 
screening against the full inclusion criteria prior to 
inclusion in the systematic review. The study selection 
process will be reported graphically using the PRISMA 
flow diagram.
data extraction
Data will be extracted by one author (SN) under the 
supervision of a second author (GP) using an agreed, 
standard data extraction spreadsheet in Microsoft 
Excel. A random selection of five papers will be used 
to pilot the data extraction spreadsheet and modifica-
tions will be made if necessary. The following data will 
be collected (see box 1):
1. Study design characteristics: for example, prospective 
or retrospective, methodology for calculating Ki-67, 
length of follow-up, statistical methods.
2. Population characteristics: for example, histological 
subtypes, patient demographics, staging.
3. Outcomes: for example, 5-year survival statistics, HRs 
(and CIs).
Assessment of study quality
To facilitate evaluation of the quality of studies eligible 
for the meta-analysis, the Newcastle-Ottawa scale will 
be utilised.28 This tool will be used to assess each 
individual study against the following criteria: case 
selection, flow of patients through the study, clear 
methodology for Ki-67 index calculations, as well as 
outcome measurement.
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box 1 data items
Study characteristics
 ► Author.
 ► Year of publication.
 ► Study design.
 ► Antibody utilised.
 ► Methodology for calculating Ki-67.
 ► Length of follow-up.
 ► Statistical method.
For each histological subtype (ie, typical carcinoid, atypical car-
cinoid, large cell neuroendocrine cancer, small cell lung cancer)
 ► Patient number.
 ► Mean age at diagnosis (range).
 ► Male:female ratio.
 ► Tumour, node, metastases stage at diagnosis.
 ► Any prior treatment received.
 ► Tumour diameter (cm).
 ► Lymph node metastases at diagnosis (ratio of 
present:absent:unknown).
 ► Distant metastases at diagnosis (ratio of present:absent:unknown).
 ► Ki67 cut-off point (%).
Outcomes
 ► Overall survival.
 ► Disease-free survival.
 ► HRs (and CIs).
 ► Results (including p values).
Assessing risk of bias
The risk of publication bias will be evaluated using 
funnel-plot visual inspection in conjunction with Begg’s 
and Egger’s test.
data synthesis and analysis
A descriptive analysis together with summary tables of 
the characteristics of studies included in the systematic 
review will be completed. In order to determine whether 
a meta-analysis is feasible, an analysis of study heteroge-
neity will be undertaken. It is anticipated that the main 
source of study heterogeneity will be in the form of Ki-67 
cut-offs utilised as well as the clinical end-points used 
to define outcomes. Given the likelihood of variability 
between included studies, a random-effects meta-anal-
ysis will be used to calculate the combined estimates of 
survival proportions.
Patient and public involvement
Patients and the public were not involved in the develop-
ment of this systematic review protocol.
EthICS And dISSEMInAtIOn
Given that this is a systematic review of existing litera-
ture, ethical approval is not required. Findings from the 
systematic review and meta-analysis will be submitted for 
publication in a peer-reviewed journal.
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